HK1254800A1 - 2,3,4,5-四氢吡啶-6-胺衍生物 - Google Patents

2,3,4,5-四氢吡啶-6-胺衍生物 Download PDF

Info

Publication number
HK1254800A1
HK1254800A1 HK18113885.1A HK18113885A HK1254800A1 HK 1254800 A1 HK1254800 A1 HK 1254800A1 HK 18113885 A HK18113885 A HK 18113885A HK 1254800 A1 HK1254800 A1 HK 1254800A1
Authority
HK
Hong Kong
Prior art keywords
alkyloxy
alkyl
cyclopropyl
compound
polyhalo
Prior art date
Application number
HK18113885.1A
Other languages
English (en)
Chinese (zh)
Inventor
Frederik Jan Rita Rombouts
Henricus Jacobus Maria Gijsen
Sven Franciscus Anna Van Brandt
Andrés Avelino TRABANCO-SUÁREZ
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1254800A1 publication Critical patent/HK1254800A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18113885.1A 2015-09-23 2016-09-23 2,3,4,5-四氢吡啶-6-胺衍生物 HK1254800A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15186394 2015-09-23
EP15186394.1 2015-09-23
EP16172005.7 2016-05-30
EP16172005 2016-05-30
PCT/EP2016/072710 WO2017050978A1 (en) 2015-09-23 2016-09-23 2,3,4,5-tetrahydropyridin-6-amine derivatives

Publications (1)

Publication Number Publication Date
HK1254800A1 true HK1254800A1 (zh) 2019-07-26

Family

ID=56985626

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113885.1A HK1254800A1 (zh) 2015-09-23 2016-09-23 2,3,4,5-四氢吡啶-6-胺衍生物

Country Status (14)

Country Link
US (1) US20180334447A1 (cg-RX-API-DMAC7.html)
EP (1) EP3353163B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018527387A (cg-RX-API-DMAC7.html)
KR (1) KR20180053357A (cg-RX-API-DMAC7.html)
CN (1) CN108026069A (cg-RX-API-DMAC7.html)
AU (1) AU2016328589A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018005591A2 (cg-RX-API-DMAC7.html)
CA (1) CA2995161A1 (cg-RX-API-DMAC7.html)
EA (1) EA035026B1 (cg-RX-API-DMAC7.html)
HK (1) HK1254800A1 (cg-RX-API-DMAC7.html)
IL (1) IL258217A (cg-RX-API-DMAC7.html)
MX (1) MX2018003565A (cg-RX-API-DMAC7.html)
TW (1) TW201726651A (cg-RX-API-DMAC7.html)
WO (1) WO2017050978A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019208509A1 (en) * 2018-04-23 2019-10-31 Shionogi & Co., Ltd. Bicyclic heterocycle derivatives having selective bace1 inhibitory activity
BR112020021728A2 (pt) 2018-04-27 2021-01-26 Shionogi & Co., Ltd. derivados de tetra-hidropiranooxazina tendo atividade inibitória de bace1 seletiva
CN114380736B (zh) * 2020-10-21 2023-10-03 复旦大学 一种2,3,4,5-四氢吡啶类化合物的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32799A (es) * 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
WO2011077726A1 (ja) * 2009-12-24 2011-06-30 塩野義製薬株式会社 4-アミノ-1,3-チアジンまたはオキサジン誘導体
US8673894B2 (en) 2010-05-07 2014-03-18 Hoffmann-La Roche Inc. 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
AR081587A1 (es) * 2010-06-09 2012-10-03 Janssen Pharmaceutica Nv DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE)
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
US8815841B2 (en) 2011-02-18 2014-08-26 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
WO2014059185A1 (en) * 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
AU2014223334C1 (en) 2013-03-01 2018-10-18 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US20170066741A1 (en) 2014-02-19 2017-03-09 H. Lundbeck A/S 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease

Also Published As

Publication number Publication date
MX2018003565A (es) 2018-06-18
WO2017050978A1 (en) 2017-03-30
IL258217A (en) 2018-05-31
JP2018527387A (ja) 2018-09-20
CA2995161A1 (en) 2017-03-30
CN108026069A (zh) 2018-05-11
EP3353163A1 (en) 2018-08-01
AU2016328589A1 (en) 2018-03-01
EP3353163B1 (en) 2020-02-05
EA035026B1 (ru) 2020-04-20
US20180334447A1 (en) 2018-11-22
EA201890769A1 (ru) 2018-09-28
TW201726651A (zh) 2017-08-01
KR20180053357A (ko) 2018-05-21
BR112018005591A2 (pt) 2018-10-09

Similar Documents

Publication Publication Date Title
CN111836798B (zh) 氯胺酮的前药、其组合物和用途
CN114945566A (zh) 作为钠通道调节剂的取代四氢呋喃
TWI421250B (zh) 衍生物及其用於治療神經性疾病之用途
TW201300358A (zh) 含氮縮合雜環化合物
CN115884971A (zh) 取代的哌啶化合物及其用途
JP2025504859A (ja) 補体因子b阻害剤としてのスピロ環式ピペリジニル誘導体及びその使用
TW201331177A (zh) 治療活性組合物及其使用方法
CN106211770B (zh) 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮
RU2712455C1 (ru) 6,7,8,9-тетрагидро-5h-пиридо[2,3-d]азепиновые лиганды дофаминовых рецепторов d3
CN111183138A (zh) 异色满化合物以及用途
KR20200139702A (ko) 칼페인 조정자 및 그 치료학적 용도
JP2025003508A (ja) 抗ウイルス1,3-ジ-オキソ-インデン化合物
CN100418525C (zh) 对钙通道α-2-δ亚基具有亲合力的脯氨酸衍生物
TW202304864A (zh) 1,3-取代的環丁基衍生物及其用途
JP2023503320A (ja) 肝臓x受容体アゴニストとしての1,2,4-オキサジアゾール誘導体
EP3353163B1 (en) 2,3,4,5-tetrahydropyridin-6-amine derivatives
JP2020522550A (ja) 軟骨形成を誘導するための化合物及び組成物
EP4428128A1 (en) 2-(aryl-2-yl) morpholine and deuterated derivative thereof, preparation method therefor and application thereof
EP4324835A1 (en) Pyrimidinone derivative and preparation method therefor, pharmaceutical composition, and use
JP2023549962A (ja) Pu.1阻害剤としての化合物
TWI810547B (zh) Pd-l1拮抗劑化合物
HK40119559A (en) Compounds and compositions for treating conditions associated with lpa receptor activity
WO2025252235A1 (zh) 一种用于调节β2整联蛋白的化合物及其药物组合物
CA3202256A1 (en) Substituted cyclohexanecarboxamides, their preparation and their therapeutic application
EP2797898B9 (fr) Derives piperazinyles pour le traitement de cancers